# Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)

> **NCT02380235** · PHASE4 · UNKNOWN · sponsor: **Changchun GeneScience Pharmaceutical Co., Ltd.** · enrollment: 600 (estimated)

## Conditions studied

- Growth Hormone Deficiency

## Interventions

- **BIOLOGICAL:** PEG-somatropin
- **BIOLOGICAL:** PEG-somatropin

## Key facts

- **NCT ID:** NCT02380235
- **Lead sponsor:** Changchun GeneScience Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2014-12
- **Primary completion:** 2017-06
- **Final completion:** 2017-07
- **Target enrollment:** 600 (ESTIMATED)
- **Last updated:** 2017-06-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02380235

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02380235, "Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children (Clinical Trial I)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02380235. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*